Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a.
Lamb
Matthew W
MW
Department of Clinical Science, Hoffmann-LaRoche Inc., 340 Kingsland Street, Nutley, NJ 07110-1199, USA. matthew.lamb@roche.com
Martin
Nancy E
NE
D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001835:Body Weight; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008657:Metabolic Clearance Rate; D009765:Obesity / Q000150:complications / Q000378:metabolism; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011994:Recombinant Proteins; D014018:Tissue Distribution
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a